Trial Profile
A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary) ; Diphenhydramine
- Indications Restless legs syndrome
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 25 Jul 2013 Lead trial center changed as reported by ClinicalTrials.gov.
- 13 Apr 2011 New trial record